| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhang,Ming-Zheng | Chairman | 18.13% | MEDIGEN BIOTECHNOLOGY CORP. |
| Chen,Jin-Yan | Director | 18.13% | MEDIGEN BIOTECHNOLOGY CORP. |
| Chen,Can-Jian | Director | 0.17% | |
| Lin,Jia-Xiu | Director | 0.00% | |
| Wu,Ming-Yi | Independent Director | 0.00% | |
| Li,Yao-Ji | Independent Director | 0.00% | |
| Su,Peng-Fei | Independent Director | 0.01% |
Change Company Name to MEDIGEN VACCINE BIOLOGICS CORPORATION
2024/06/25
Change Person in Charge to Zhang,Ming-Zheng
2023/03/15
Change Company Name to HIGH-END VACCINE AND BIOLOGICAL PRODUCTS CO., LTD. (FORMER NAME: GYA VACCINE AND BIOLOGICAL PRODUCTS CO., LTD.)
2022/08/11
Change Capital to 5,000,000,000
2022/07/08
Change Capital to 3,000,000,000
2019/07/08
Change Company Name to MEDIGEN VACCINE BIOLOGICS CORPORATION
2017/06/07
Change Capital to 2,000,000,000
2015/12/15
Change Company Name to GYA VACCINE BIOLOGICS CO., LTD.
2015/05/07
Change Capital to 1,000,000,000
2014/01/20
下載完整報告查看完整數據
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 605,637 | 389,624 | 365,042 |
| Operating cost | 209,215 | 159,402 | 577,644 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 396,422 | 230,222 | -212,602 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 396,422 | 230,222 | -212,602 |
| Operating expenses | 542,088 | 1,444,051 | 1,323,663 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -145,666 | -1,213,829 | -1,536,265 |
| Non-operating income and expenses | 65,201 | 53,994 | 61,692 |
| Net profit (loss) before tax | -80,465 | -1,159,835 | -1,474,573 |
| Income tax expense (benefits) | 0 | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -80,465 | -1,159,835 | -1,474,573 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -80,465 | -1,159,835 | -1,474,573 |
| Other comprehensive profit (loss), net | 66,244 | -54,267 | 82,577 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -14,221 | -1,214,102 | -1,391,996 |
| Net profit (loss) attributable to owners of parent company | -80,465 | -1,159,835 | -1,474,573 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -14,221 | -1,214,102 | -1,391,996 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | -3 | -4 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 40,753 | -478,335 | -1,100,963 |
| Net cash inflows (outflows) from investing activities | 1,017,676 | 669,829 | -2,397,917 |
| Net cash inflow (outflow) from financing activities | -1,736,041 | 1,593 | 3,323,091 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 105 | -4,222 | 352 |
| Increase (decrease) in cash and cash equivalents in the current period | -677,507 | 188,865 | -175,437 |
| Beginning balance of cash and cash equivalents | 1,393,120 | 1,204,255 | 1,379,692 |
| Ending balance of cash and cash equivalents | 715,613 | 1,393,120 | 1,204,255 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 2,556,914 | 4,401,325 | 5,462,422 |
| Non-current asset | 1,806,992 | 1,691,321 | 1,885,267 |
| Total asset | 4,363,906 | 6,092,646 | 7,347,689 |
| Current liability | 214,218 | 1,991,711 | 355,232 |
| Non-current liability | 299,701 | 254,356 | 1,963,452 |
| Total liability | 513,919 | 2,246,067 | 2,318,684 |
| share capital | 3,287,491 | 3,286,081 | 3,280,312 |
| Equity - secruity token | - | - | - |
| capital reserve | 407,381 | 1,550,997 | 2,798,085 |
| retained earning | 61,020 | -1,018,350 | -1,131,510 |
| Other equity | 94,095 | 27,851 | 82,118 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 3,849,987 | 3,846,579 | 5,029,005 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 3,849,987 | 3,846,579 | 5,029,005 |
| Share capital awaiting retirement (unit: share) | - | - | 0 |
| Issued shares of advance equity (unit: shares) | 15,000 | 0 | 191,300 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 11 | 11 | 15 |
| 標案名稱 | 機關名稱 | 決標日期 | 決標金額 | 是否得標 |
|---|---|---|---|---|
| 「113年度四價流感疫苗」 | 衛生福利部疾病管制署 | 113/04/15 | 106671600.0 | 是 |
| 112年度四價流感疫苗採購案 | 衛生福利部疾病管制署 | 112/04/18 | 166951120.0 | 是 |
| 110年國內COVID-19疫苗緊急採購案 | 衛生福利部疾病管制署 | 110/05/28 | 4030000000.0 | 是 |
| 新竹科學工業園區新竹生物醫學園區景觀餐廳委託經營案 | 科技部新竹科學工業園區管理局 | 107/11/22 | 否 | |
| 「105年度甲醛不活化腸病毒71型B4亞型原液」 | 衛生福利部食品藥物管理署 | 105/11/07 | 否 |
